InvestSMART

The article you are trying to access does not exist, however, here are some articles you may be interested in.

Imricor Medical Systems Inc (ASX: IMR) - Announcements

- Current share price for IMR : $1.950

ASX company news and announcements for Imricor Medical Systems Inc (IMR) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Imricor Medical Systems Inc (IMR) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Imricor Medical Systems Inc (IMR), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Imricor Medical Systems Inc (IMR)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$699 Imricor U.S. Commercial Momentum Accelerates 10 Aug 2026 8:50AM $1.900 $1.950 risen by 2.63%
$699 1H 2026 Investor Presentation 10 Aug 2026 8:39AM $1.900 $1.950 risen by 2.63%
$699 2026 Q2 Form 10-Q 10 Aug 2026 8:39AM $1.900 $1.950 risen by 2.63%
$699 Q2 CY2026 Quarterly Activities Report & Form 10-Q Submission 10 Aug 2026 8:38AM $1.900 $1.950 risen by 2.63%
$699 Philips Declares Compatibility with Imricor 7 Aug 2026 8:31AM $1.895 $1.950 risen by 2.90%
$699 Q2 FY26 Results Webinar Notification 4 Aug 2026 8:58AM $1.860 $1.950 risen by 4.84%
$699 Imricor Launches U.S. Commercial Operations 27 Jul 2026 8:34AM $1.920 $1.950 risen by 1.56%
$699 Imricor Submits All Remaining 510(k) Devices to FDA 20 Jul 2026 9:25AM $1.635 $1.950 risen by 19.27%
$699 Notification regarding unquoted securities - IMR 14 Jul 2026 5:19PM $1.670 $1.950 risen by 16.77%
$699 Cleansing Notice 13 Jul 2026 11:35AM $1.850 $1.950 risen by 5.41%
$699 Application for quotation of securities - IMR 13 Jul 2026 11:30AM $1.850 $1.950 risen by 5.41%
$699 Imricor Receives FDA Pediatric Clearances for iMR Device 2 Jul 2026 8:33AM $1.805 $1.950 risen by 8.03%
$699 Form S-8 Registration Statement 26 Jun 2026 8:58AM $1.785 $1.950 risen by 9.24%
$699 Submission of the Third PMA Module to the US FDA for Review 11 Jun 2026 8:55AM $1.680 $1.950 risen by 16.07%
$699 Granting of ASX Waiver - US Financial Reporting Requirements 27 May 2026 9:13AM $1.750 $1.950 risen by 11.43%
$699 Notification of cessation of securities - IMR 21 May 2026 9:36AM $1.775 $1.950 risen by 9.86%
$699 Update - Notification regarding unquoted securities - IMR 21 May 2026 9:33AM $1.775 $1.950 risen by 9.86%
$699 Appendix 3Y - AD 20 May 2026 9:57AM $1.790 $1.950 risen by 8.94%
$699 Appendix 3Y - PM 20 May 2026 9:56AM $1.790 $1.950 risen by 8.94%
$699 Appendix 3Y - AM 20 May 2026 9:56AM $1.790 $1.950 risen by 8.94%
$699 Appendix 3Y - MT 20 May 2026 9:55AM $1.790 $1.950 risen by 8.94%
$699 Appendix 3Y - SW 20 May 2026 9:53AM $1.790 $1.950 risen by 8.94%
$699 Notification regarding unquoted securities - IMR 20 May 2026 9:34AM $1.790 $1.950 risen by 8.94%
$699 Becoming a substantial holder 19 May 2026 6:00PM $1.790 $1.950 risen by 8.94%
$699 Application for quotation of securities - IMR 18 May 2026 9:44AM $1.845 $1.950 risen by 5.69%

1 - 25 of 596 results

Page 1 of 24

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.